Cardiovascular Effects in Rats following Exposure to a Receptor Tyrosine Kinase Inhibitor

Toxicologic Pathology

Volumn 38, Issue 3, 2010, Pages 416-428

  Aguirre, Shirley A ^a   Heyen, Jonathan R ^a   Collette, Walter ^a   Bobrowski, Walter ^a   Blasi, Eileen R ^a  

^a PFIZER INC   (United States)

Author keywords

c Met; cardiotoxicity; phosphodiesterases; receptor tyrosine kinase inhibitor

Indexed keywords

6 [1 [6 (1 METHYL 1H PYROAZOL 4 YL) [1,2,4] TRIAZOLO [4,3 B] PYRIDAZIN 3 YL ETHYL]QUINOLINE]; PF 04254644; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CELL DEGENERATION; CLINICAL OBSERVATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; TACHYCARDIA; TELEMETRY; TOXICITY TESTING; TOXICOKINETICS;

ANIMALS; HEART; HEART RATE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHORIC DIESTER HYDROLASES; PROTEIN KINASE INHIBITORS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 77952487921     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310364027     Document Type: Article

References (33)

1. Bender A. T. Beavo J. A. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacological Reviews 58, 488–520.
2. Blasi E. R. Rocha R. Rudolph A. E. Blomme E. A. Polly M. L. McMahon E. G. (2003). Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney International 63, 1791–800.
3. Center for Drug Evaluation and Research (2002). Milrinone Lactate Printed Labelling. In Application 07582. Baxter Health Care, Deerfield, IL.
4. Desjardins S. Cauchy M. J. (1995). Comparative cardiac effects of milrinone and sodium nitroprusside in conscious rats. Drug and Chemical Toxicology 18, 43–59.
5. Dhalla N. Yates Y. Naimark B. Dhalla K. Beamish R. Ostadal B. (1992). Cardiotoxicity of Catecholamines and Related Agents. Raven Press, New York.
6. Earl C. Q. Linden J. Weglicki W. B. (1986a). Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone. Journal of Cardiovascular Pharmacology 8, 864–72.
7. Earl C. Q. Linden J. Weglicki W. B. (1986b). Inhibition of cyclic AMP-dependent protein kinase activity by the cardiotonic drugs amrinone and milrinone. Life Sciences 39, 1901–8.
8. Eder J. P. Vande Woude G. F. Boerner S. A. LoRusso P. M. (2009). Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15, 2207–14.
9. Force T. Kerkela R. (2008). Cardiotoxicity of the new cancer therapeutics—mechanisms of, and approaches to, the problem. Drug Discovery Today 13, 778–84.
10. Heyen J. R. Blasi E. R. Nikula K. Rocha R. Daust H. A. Frierdich G. Van Vleet J. F. De Ciechi P. McMahon E. G. Rudolph A. E. (2002). Structural, functional, and molecular characterization of the SHHF model of heart failure. Amer J Physiol Heart Circul Physiol 283, H1775–84.
11. Kaufmann M. A. Pargger H. (1994). Role of phosphodiesterase inhibitors in acute myocardial contractile failure. Anaesthetic Pharmacol Review 2, 324–31.
12. R., Kerkela, L., Grazette, R., Yacobi, C., Iliescu, R., Patten, C., Beahm, B., Walters, S., Shevtsov, S., Pesant, F.J., Clubb, A., Rosenzweig, R.N., Salomon, E.E.A., Van, J., Alroy, J.B., Durand, T., Force, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nature Medicine, (2006), 12, 908-916
13. Kitta K. Day R. M. Kim Y. Torregroza I. Evans T. Suzuki Y. J. (2003). Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells. J of Biol Chem 278, 4705–12.
14. Krause D. S. Van Etten R. A. (2005). Tyrosine kinases as targets for cancer therapy. N Engl J Med 353, 172–87.
15. Lugnier C. (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Therapeut 109, 366–98.
16. Miyamoto S. Murphy A. N. Brown J. H. (2009). Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to rescue. J Bioenerg Biomembr Epub April 18.
17. Movsesian M. A. (1999). Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. J of the Amer College Cardiol 34, 318–24.
18. Omori K. Kotera J. (2007). Overview of PDEs and their regulation. Circulation Res 100, 309–27.
19. Perera T. Lavrijssen T. Janssens B. Geerts T. King P. Mevellec L. Cummings M. Lu T. Johnson D. Page M. (2008). JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models. In 99th AACR Annual Meeting, April 12-16, San Diego, CA.
20. Ramirez D. S. Heyen J. R. Brunton N. Scatchard J. Lui R. Zager M. Kozminski K. McHarg A. D. (2008). Phosphodiestase-3 inhibition- cardiovascular effects and the translation from in vitro to in vivo and across species. In 8th Annual Meeting Safety Pharmacology Society (S. P. Society, ed.), p. 161. Safety Pharmacology Society, Madison, WI.
21. Rona G. (1985). Catecholamine cardiotoxicity. J Mol and Cell Cardiol 17, 291–306.
22. Schlepper M. Thormann J. Mitrovic V. (1989). Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors. Basic Research in Cardiology 84 Suppl 1, 197–212.
23. H., Shen, M., Nambu, M., Tran-Dube, C., Johnson, M., McTigue, M., Parker, S., Yamazaki, H.Y., Zou, J.G., Christensen, J.J.J., Cui, Discovery of PF-04254644: a highly potent and exquisitively selective c-Met/HGFR inhibitor, In 236th ACS Nat Meet, August 17-21, Abst MEDI 238, ACS, Philadelphia, (2008)
24. Shin D. D. Brandimarte F. De Luca L. Sabbah H. N. Fonarow G. C. Filippatos G. Komajda M. Gheorghiade M. (2007). Review of current and investigational pharmacologic agents for acute heart failure syndromes. American Journal of Cardiology 99, 4A–23A.
25. Sircar I. Steffen R. P. Bobowski G. Burke S. E. Newton R. S. Weishaar R. E. Bristol J. A. Evans D. B. (1989). Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. Journal of Medicinal Chemistry 32, 342–50.
26. Stellrecht C. M. Gandhi V. (2009). MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Letters 280, 1–14.
27. Ueda H. Nakamura T. Matsumoto K. Sawa Y. Matsuda H. Nakamura T. (2001). A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc-Res 51, 41–50.
28. T.J., van Steeg, J., Freijer, M., Danhof, E.E.M., de Lange, Pharmacokinetic-pharmacodynamic modelling of S—atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint, British J Pharmacol, (2007), 151, 356-366
29. Vinogradova T. M. Sirenko S. Lyashkov A. E. Younes A. Li Y. Zhu W. Yang D. Ruknudin A. M. Spurgeon H. Lakatta E. G. (2008). Constitutive phosphodiesterase activity restricts spontaneous beating rate of cardiac pacemaker cells by suppressing local Ca2+ releases. Circulation Res 102, 761–9.
30. Wang Y. P. (2007). Mitogen-activated protein kinases in heart development and diseases. Circulation 116, 1413–23.
31. York M. Scudamore C. Brady S. Chen C. Wilson S. Curtis M. Evans G. Griffiths W. Whayman M. Williams T. Turton J. (2007). Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover Wistar rat. Toxicol Path 35, 606–17.
32. Zhang J. Knapton A. Lipshultz S. E. Weaver J. L. Herman E. H. (2008). Isoproterenol-induced cardiotoxicity in Sprague-Dawley rats: Correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol Pathol 36, 277–8.
33. Zou H. Li Q. Lee J. Burgess K. Ozeck M. Parker M. Pavlicek A. Cui J. Bender S. Christensen J. (2008). Receptor tyrosine kinase cross talk affects tumor cell sensitivity to RTK inhibitors. In 99th Annual Meeting American Association for Cancer Research (AACR, ed.), vol. 2008, pp. LB-198-. Late Breaking Abstracts & Posters AACR, San Diego, CA.